与泰杜格胺相关的胰腺炎:通过食品和药物管理局不良事件报告系统 (FAERS) 数据库进行不成比例分析
Joyce H Gu1, Zachary Sheingold2, Mark Samarneh3
1Medicine, Lake Erie College of Osteopathic Medicine, Greensburg, USA.
Cureus
|October 1, 2024
概括
用于短肠综合征的特杜格卢提德与胰腺炎的风险增加有显著的关联. 医疗保健提供者应在治疗期间仔细监测患者是否有这种不良事件.
科学领域:
- 胃肠病学 胃肠病学
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
背景情况:
- 泰杜格卢提德是一种类似于葡萄糖的-2-类同类物,通过减少对肠道支的依赖来治疗短肠综合征 (SBS).
- 由于这种情况的罕见性,特杜格卢的安全性,是一种相对较新的SBS治疗,尚未完全理解.
- 临床报告表明,特杜格卢提德使用与胰腺酶升高或胰腺炎之间存在潜在联系.
研究的目的:
- 系统地调查 teduglutide 和胰腺炎风险之间的关联.
- 为了量化服用泰杜格胺的患者胰腺炎事件的不成比例.
主要方法:
- 使用美国食品和药物管理局不良事件报告系统 (FAERS) 数据进行了病例对照不成比例分析.
- 数据涵盖2020年第一季度至2024年第一季度,包括11,696份泰杜格胺不良事件报告.
- 统计方法包括报告几率比率 (ROR),比例报告比率 (PRR),实证贝叶斯几何平均值 (EBGM) 和信息组件 (IC).
主要成果:
- 在11,696份报告中,79例胰腺炎病例在使用泰杜格胺的患者中被确定.
- 不成比例分析显示出一个统计学上显著的关联:ROR为3.73,PRR为3.71,EBGM为3.70,IC为1.84.
- 所有计算的指标都超过了指标值,表明teduglutide和胰腺炎之间存在显著联系.
结论:
- 在teduglutide使用和胰腺炎风险增加之间存在统计学上显著的关联.
- 这些发现强调了在接受泰杜格卢类药物治疗的患者中保持警性胰腺炎监测的重要性.
- 进一步的药物监测至关重要,以充分阐明泰杜格胺在胰腺并发症方面的安全性.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70
Insulin: Dosing Regimen and Adverse Effects
155
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
155
Dipeptidyl Peptidase 4 Inhibitors
177
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
177
Glucagon-like Receptor Agonists
302
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
302
Acute Pancreatitis II: Clinical Manifestations and Management
95
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
95


